Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism

The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug's safety profile and metabolic efficacy mark a significant step forward in hepatology.
Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Produces Rapid Reductions in Liver Fat and AI‑Quantified Fibrosis in Early Phase Trials — Promise and Unanswered Questions

Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoints are needed to establish meaningful benefit.
Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial
Posted inClinical Updates Gastroenterology Internal Medicine news Specialties

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and diabetic populations.